{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:30:17Z","timestamp":1773721817780,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SFRH\/BD\/144719\/2019"],"award-info":[{"award-number":["SFRH\/BD\/144719\/2019"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["2021.07508.BD"],"award-info":[{"award-number":["2021.07508.BD"]}]},{"name":"CAPES Print","award":["88887.470236\/2019-00"],"award-info":[{"award-number":["88887.470236\/2019-00"]}]},{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mometasone furoate (MF) is a synthetic glucocorticoid used clinically to treat specific inflammatory disorders including superior and inferior respiratory tract. Due to its poor bioavailability we further investigated whether nanoparticles (NPs) made of zein protein may constitute a safe and effective choice to incorporate MF. Thus, in this work, we loaded MF into zein NPs aiming to evaluate possible advantages that could result from oral delivery and extend the range of MF application such as inflammatory gut diseases. MF-loaded zein NPs presented an average size in the range of 100 and 135\u00a0nm, narrow size distribution (polydispersity index\u2009&lt;\u20090.300), zeta potential of around\u2009+\u200910\u00a0mV and association efficiency of MF over 70%. Transmission electron microscopy imaging revealed that NPs had a round shape and presented a smooth surface. The zein NPs showed low MF release in a buffer that mimics the gastric condition (pH\u2009=\u20091.2) and slower and controlled MF release in the intestinal condition (pH\u2009=\u20096.8). The short and intermediate safety of zein NPs was confirmed assessing the incubation against Caco-2 and HT29-MTX intestinal cells up to 24\u00a0h. Permeability studies of MF across Caco-2\/HT29-MTX co-culture monolayer evidenced that zein NPs modulated MF transport across cell monolayer resulting in a stronger and prolonged interaction with mucus, potentially extending the time of absorption and overall local and systemic bioavailability. Overall, zein NPs showed to be suitable to carry MF to the intestine and future studies can be developed to investigate the use of MF-loaded zein NPs to treat intestinal inflammatory diseases.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s13346-023-01367-y","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T17:01:34Z","timestamp":1684515694000},"page":"2948-2959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Zein nanoparticles as oral carrier for mometasone furoate delivery"],"prefix":"10.1007","volume":"13","author":[{"given":"Priscila","family":"Zimath","sequence":"first","affiliation":[]},{"given":"Soraia","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Alex","family":"Rafacho","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-7553","authenticated-orcid":false,"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"1367_CR1","doi-asserted-by":"publisher","unstructured":"Pasieka AM, Rafacho A. Impact of glucocorticoid excess on glucose tolerance: Clinical and preclinical evidence. Metabolites. 2016;6. https:\/\/doi.org\/10.3390\/metabo6030024.","DOI":"10.3390\/metabo6030024"},{"key":"1367_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3803\/EnM.2017.32.2.180","volume":"32","author":"S Suh","year":"2017","unstructured":"Suh S, Park MK. Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. Endocrinol Metab. 2017;32:180. https:\/\/doi.org\/10.3803\/EnM.2017.32.2.180.","journal-title":"Endocrinol Metab"},{"key":"1367_CR3","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1183\/09031936.02.02472001","volume":"20","author":"RJH Austin","year":"2002","unstructured":"Austin RJH, Maschera B, Walker A, et al. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002;20:1386\u201392. https:\/\/doi.org\/10.1183\/09031936.02.02472001.","journal-title":"Eur Respir J"},{"key":"1367_CR4","doi-asserted-by":"publisher","first-page":"S434","DOI":"10.1016\/S0091-6749(98)70155-1","volume":"101","author":"M Johnson","year":"1998","unstructured":"Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S434\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1367_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1067\/mai.2000.110798","volume":"106","author":"JE Fish","year":"2000","unstructured":"Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol. 2000;106:852\u201360. https:\/\/doi.org\/10.1067\/mai.2000.110798.","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"1367_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1177\/009127000004001107","volume":"40","author":"MB Affrime","year":"2000","unstructured":"Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol. 2000;40:1227\u201336.","journal-title":"J Clin Pharmacol"},{"key":"1367_CR7","doi-asserted-by":"publisher","unstructured":"Zimath PL, Almeida MS, Bruxel MA, Rafacho A. Oral mometasone furoate administration preserves anti-inflammatory action with fewer metabolic adverse effects in rats. Biochem Pharmacol. 2003;210:115486. https:\/\/doi.org\/10.1016\/J.BCP.2023.115486.","DOI":"10.1016\/J.BCP.2023.115486"},{"key":"1367_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3109\/08923970902874693","volume":"31","author":"M Ogawa","year":"2009","unstructured":"Ogawa M, Sakonjo H, Kamei C. Dissociation of local anti-inflammatory effect and systemic effects of mometasone furoate in mice. Immunopharmacol Immunotoxicol. 2009;31:601\u20136. https:\/\/doi.org\/10.3109\/08923970902874693.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1367_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/J.COCIS.2010.12.005","volume":"16","author":"L Plapied","year":"2011","unstructured":"Plapied L, Duhem N, des Rieux A, Pr\u00e9at V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci. 2011;16:228\u201337. https:\/\/doi.org\/10.1016\/J.COCIS.2010.12.005.","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"1367_CR10","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/J.DRUDIS.2014.04.011","volume":"19","author":"U Agrawal","year":"2014","unstructured":"Agrawal U, Sharma R, Gupta M, Vyas SP. Is nanotechnology a boon for oral drug delivery? Drug Discov Today. 2014;19:1530\u201346. https:\/\/doi.org\/10.1016\/J.DRUDIS.2014.04.011.","journal-title":"Drug Discov Today"},{"key":"1367_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/ard.2003.009944","volume":"63","author":"JM Metselaar","year":"2004","unstructured":"Metselaar JM, van den Berg WB, Holthuysen AEM, et al. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis. 2004;63:348\u201353. https:\/\/doi.org\/10.1136\/ard.2003.009944.","journal-title":"Ann Rheum Dis"},{"key":"1367_CR12","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2217\/nnm.15.45","volume":"10","author":"LK Prasad","year":"2015","unstructured":"Prasad LK, O\u2019Mary H, Cui Z. Nanomedicine delivers promising treatments for rheumatoid arthritis. Nanomedicine. 2015;10:2063\u201374.","journal-title":"Nanomedicine"},{"key":"1367_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2017.02.032","volume":"252","author":"M Yang","year":"2017","unstructured":"Yang M, Feng X, Ding J, et al. Nanotherapeutics relieve rheumatoid arthritis. J Control Release. 2017;252:108\u201324.","journal-title":"J Control Release"},{"key":"1367_CR14","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1021\/acsomega.0c00111","volume":"5","author":"J Far","year":"2020","unstructured":"Far J, Abdel-Haq M, Gruber M, Abu Ammar A. Developing Biodegradable Nanoparticles Loaded with Mometasone Furoate for Potential Nasal Drug Delivery. ACS Omega. 2020;5:7432\u20139. https:\/\/doi.org\/10.1021\/acsomega.0c00111.","journal-title":"ACS Omega"},{"key":"1367_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/2211738506666180523112513","volume":"6","author":"N Kaur","year":"2018","unstructured":"Kaur N, Sharma K, Bedi N. Topical Nanostructured Lipid Carrier Based Hydrogel of Mometasone Furoate for the Treatment of Psoriasis. Pharm Nanotechnol. 2018;6:133\u201343. https:\/\/doi.org\/10.2174\/2211738506666180523112513.","journal-title":"Pharm Nanotechnol"},{"key":"1367_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/J.JCONREL.2011.12.024","volume":"160","author":"R Ulmansky","year":"2012","unstructured":"Ulmansky R, Turjeman K, Baru M, et al. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J Control Release. 2012;160:299\u2013305. https:\/\/doi.org\/10.1016\/J.JCONREL.2011.12.024.","journal-title":"J Control Release"},{"key":"1367_CR17","doi-asserted-by":"publisher","first-page":"40696","DOI":"10.1002\/APP.40696","volume":"131","author":"Y Luo","year":"2014","unstructured":"Luo Y, Wang Q. Zein-based micro- and nano-particles for drug and nutrient delivery: A review. J Appl Polym Sci. 2014;131:40696. https:\/\/doi.org\/10.1002\/APP.40696.","journal-title":"J Appl Polym Sci"},{"key":"1367_CR18","doi-asserted-by":"publisher","unstructured":"Esposito D, Conte C, d\u2019Angelo I, et al. Mucoadhesive zein\/beta-cyclodextrin nanoparticles for the buccal delivery of curcumin. Int J Pharm. 2020;586. https:\/\/doi.org\/10.1016\/J.IJPHARM.2020.119587.","DOI":"10.1016\/J.IJPHARM.2020.119587"},{"key":"1367_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/J.COCIS.2014.08.001","volume":"19","author":"AR Patel","year":"2014","unstructured":"Patel AR, Velikov KP. Zein as a source of functional colloidal nano- and microstructures. Curr Opin Colloid Interface Sci. 2014;19:450\u20138. https:\/\/doi.org\/10.1016\/J.COCIS.2014.08.001.","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"1367_CR20","doi-asserted-by":"publisher","unstructured":"Reboredo C, Gonz\u00e1lez-Navarro CJ, Mart\u00ednez-L\u00f3pez AL, et al. Zein-Based Nanoparticles as Oral Carriers for Insulin Delivery. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14010039.","DOI":"10.3390\/pharmaceutics14010039"},{"key":"1367_CR21","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/S13346-020-00796-3","volume":"10","author":"L Inchaurraga","year":"2020","unstructured":"Inchaurraga L, Mart\u00ednez-L\u00f3pez AL, Martin-Arbella N, Irache JM. Zein-based nanoparticles for the oral delivery of insulin. Drug Deliv Transl Res. 2020;10:1601\u201311. https:\/\/doi.org\/10.1007\/S13346-020-00796-3.","journal-title":"Drug Deliv Transl Res"},{"key":"1367_CR22","doi-asserted-by":"publisher","unstructured":"Reboredo C, Gonz\u00e1lez-Navarro CJ, Mart\u00ednez-L\u00f3pez AL, Irache JM. Oral administration of zein-based nanoparticles reduces glycemia and improves glucose tolerance in rats. Int J Pharm. 2022;628. https:\/\/doi.org\/10.1016\/J.IJPHARM.2022.122255.","DOI":"10.1016\/J.IJPHARM.2022.122255"},{"key":"1367_CR23","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1021\/jf505694e","volume":"63","author":"R Penalva","year":"2015","unstructured":"Penalva R, Esparza I, Larraneta E, et al. Zein-Based Nanoparticles Improve the Oral Bioavailability of Resveratrol and Its Anti-inflammatory Effects in a Mouse Model of Endotoxic Shock. J Agric Food Chem. 2015;63:5603\u201311. https:\/\/doi.org\/10.1021\/jf505694e.","journal-title":"J Agric Food Chem"},{"key":"1367_CR24","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2217\/nnm-2017-0075","volume":"12","author":"JM Irache","year":"2017","unstructured":"Irache JM, Gonz\u00e1lez-Navarro CJ. Zein nanoparticles as vehicles for oral delivery purposes. Nanomedicine. 2017;12:1209\u201311.","journal-title":"Nanomedicine"},{"key":"1367_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/S13346-022-01286-4","author":"F Hameedat","year":"2023","unstructured":"Hameedat F, Pinto S, Marques J, et al. Functionalized zein nanoparticles targeting neonatal Fc receptor to enhance lung absorption of peptides. Drug Deliv Transl Res. 2023. https:\/\/doi.org\/10.1007\/S13346-022-01286-4.","journal-title":"Drug Deliv Transl Res"},{"key":"1367_CR26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s13346-020-00738-z","volume":"10","author":"R Nunes","year":"2020","unstructured":"Nunes R, Bai\u00e3o A, Monteiro D, et al. Zein nanoparticles as low-cost, safe, and effective carriers to improve the oral bioavailability of resveratrol. Drug Deliv Transl Res. 2020;10:826\u201337. https:\/\/doi.org\/10.1007\/s13346-020-00738-z.","journal-title":"Drug Deliv Transl Res"},{"key":"1367_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/J.JCONREL.2014.06.036","volume":"189","author":"R Paliwal","year":"2014","unstructured":"Paliwal R, Palakurthi S. Zein in controlled drug delivery and tissue engineering. J Control Release. 2014;189:108\u201322. https:\/\/doi.org\/10.1016\/J.JCONREL.2014.06.036.","journal-title":"J Control Release"},{"key":"1367_CR28","doi-asserted-by":"publisher","first-page":"18062","DOI":"10.1021\/ACSAMI.9B00152","volume":"11","author":"MS Islam","year":"2019","unstructured":"Islam MS, Reineke J, Kaushik R, et al. Bioadhesive Food Protein Nanoparticles as Pediatric Oral Drug Delivery System. ACS Appl Mater Interfaces. 2019;11:18062\u201373. https:\/\/doi.org\/10.1021\/ACSAMI.9B00152.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1367_CR29","doi-asserted-by":"publisher","unstructured":"Bijsmans ITGW, Guercini C, Ramos Pittol JM, et al. The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. Sci Rep. 2015;5. https:\/\/doi.org\/10.1038\/srep14086.","DOI":"10.1038\/srep14086"},{"key":"1367_CR30","unstructured":"Vichare VS, Choudhari VP, Reddy MV. Simultaneous Estimation of Mometasone Furoate and Salicylic Acid in Topical Formulation By UV-Visible Spectrophotometry. 2017."},{"key":"1367_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/(sici)1520-6017(200001)89:1<63::aid-jps7>3.0.co;2-6","volume":"89","author":"C Hilgendorf","year":"2000","unstructured":"Hilgendorf C, Spahn-Langguth H, Reg\u00e5rdh CG, et al. Caco-2 versus Caco-2\/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci. 2000;89:63\u201375. https:\/\/doi.org\/10.1002\/(sici)1520-6017(200001)89:1%3c63::aid-jps7%3e3.0.co;2-6.","journal-title":"J Pharm Sci"},{"key":"1367_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/J.EJPB.2017.06.013","volume":"119","author":"A Lechanteur","year":"2017","unstructured":"Lechanteur A, Almeida A, Sarmento B. Elucidation of the impact of cell culture conditions of Caco-2 cell monolayer on barrier integrity and intestinal permeability. Eur J Pharm Biopharm. 2017;119:137\u201341. https:\/\/doi.org\/10.1016\/J.EJPB.2017.06.013.","journal-title":"Eur J Pharm Biopharm"},{"key":"1367_CR33","doi-asserted-by":"publisher","unstructured":"Levin M, Ostanina N, Gumeniuk O, et al. Development of simple and fast UV-method for the quantitative determination of mometasone furoate in a larger number of metered doses of an aqueous nasal spray of mometasone furoate. Heliyon. 2019;5:e02748. https:\/\/doi.org\/10.1016\/j.heliyon.2019.e02748.","DOI":"10.1016\/j.heliyon.2019.e02748"},{"key":"1367_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/J.TIFS.2018.07.015","volume":"79","author":"MR Kasaai","year":"2018","unstructured":"Kasaai MR. Zein and zein -based nano-materials for food and nutrition applications: A review. Trends Food Sci Technol. 2018;79:184\u201397. https:\/\/doi.org\/10.1016\/J.TIFS.2018.07.015.","journal-title":"Trends Food Sci Technol"},{"key":"1367_CR35","doi-asserted-by":"publisher","unstructured":"Patel A, Hu Y, Tiwari JK, Velikov KP. Synthesis and characterisation of zein\u2013curcumin colloidal particles. undefined. 2010;6:6192\u20136199. https:\/\/doi.org\/10.1039\/C0SM00800A.","DOI":"10.1039\/C0SM00800A"},{"key":"1367_CR36","doi-asserted-by":"publisher","unstructured":"Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23:1\u201329. https:\/\/doi.org\/10.1186\/S40824-019-0166-X.","DOI":"10.1186\/S40824-019-0166-X"},{"key":"1367_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/J.JCONREL.2016.07.051","volume":"238","author":"A Banerjee","year":"2016","unstructured":"Banerjee A, Qi J, Gogoi R, et al. Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J Control Release. 2016;238:176\u201385. https:\/\/doi.org\/10.1016\/J.JCONREL.2016.07.051.","journal-title":"J Control Release"},{"key":"1367_CR38","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1016\/J.BIOMATERIALS.2012.07.063","volume":"33","author":"C He","year":"2012","unstructured":"He C, Yin L, Tang C, Yin C. Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials. 2012;33:8569\u201378. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2012.07.063.","journal-title":"Biomaterials"},{"key":"1367_CR39","doi-asserted-by":"publisher","unstructured":"Danaei M, Dehghankhold M, Ataei S, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018;10. https:\/\/doi.org\/10.3390\/PHARMACEUTICS10020057.","DOI":"10.3390\/PHARMACEUTICS10020057"},{"key":"1367_CR40","doi-asserted-by":"publisher","unstructured":"Abdelsalam AM, Somaida A, Ambreen G, et al. Surface tailored zein as a novel delivery system for hypericin: Application in photodynamic therapy. Mater Sci Eng C Mater Biol Appl. 2021;129. https:\/\/doi.org\/10.1016\/J.MSEC.2021.112420.","DOI":"10.1016\/J.MSEC.2021.112420"},{"key":"1367_CR41","doi-asserted-by":"publisher","unstructured":"Nakamura H, Watano S. Direct Permeation of Nanoparticles across Cell Membrane: A Review. Kona Pow Particle J. 2018;2018:49\u201365. https:\/\/doi.org\/10.14356\/KONA.2018011.","DOI":"10.14356\/KONA.2018011"},{"key":"1367_CR42","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1208\/S12249-012-9816-1","volume":"13","author":"S Podaralla","year":"2012","unstructured":"Podaralla S, Perumal O. Influence of formulation factors on the preparation of zein nanoparticles. AAPS PharmSciTech. 2012;13:919\u201327. https:\/\/doi.org\/10.1208\/S12249-012-9816-1.","journal-title":"AAPS PharmSciTech"},{"key":"1367_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/J.FOODHYD.2017.01.022","volume":"69","author":"CJ Cheng","year":"2017","unstructured":"Cheng CJ, Jones OG. Stabilizing zein nanoparticle dispersions with \u03b9-carrageenan. Food Hydrocoll. 2017;69:28\u201335. https:\/\/doi.org\/10.1016\/J.FOODHYD.2017.01.022.","journal-title":"Food Hydrocoll"},{"key":"1367_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/J.FOODCHEM.2013.07.058","volume":"142","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Niu Y, Luo Y, et al. Fabrication, characterization and antimicrobial activities of thymol-loaded zein nanoparticles stabilized by sodium caseinate-chitosan hydrochloride double layers. Food Chem. 2014;142:269\u201375. https:\/\/doi.org\/10.1016\/J.FOODCHEM.2013.07.058.","journal-title":"Food Chem"},{"key":"1367_CR45","doi-asserted-by":"publisher","unstructured":"Pascoli M, de Lima R, Fraceto LF. Zein Nanoparticles and Strategies to Improve Colloidal Stability: A Mini-Review. Front Chem. 2018;6. https:\/\/doi.org\/10.3389\/FCHEM.2018.00006.","DOI":"10.3389\/FCHEM.2018.00006"},{"key":"1367_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/J.COLSURFA.2016.04.038","volume":"503","author":"T Chuacharoen","year":"2016","unstructured":"Chuacharoen T, Sabliov CM. Stability and controlled release of lutein loaded in zein nanoparticles with and without lecithin and pluronic F127 surfactants. Colloids Surf A Physicochem Eng Asp. 2016;503:11\u20138. https:\/\/doi.org\/10.1016\/J.COLSURFA.2016.04.038.","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"1367_CR47","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1773-2247(05)50048-0","volume":"15","author":"P Hurtado-L\u00f3pez","year":"2005","unstructured":"Hurtado-L\u00f3pez P, Murdan S. Formulation and characterisation of zein microspheres as delivery vehicles. J Drug Deliv Sci Technol. 2005;15:267\u201372. https:\/\/doi.org\/10.1016\/S1773-2247(05)50048-0.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1367_CR48","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1021\/JF204194Z","volume":"60","author":"Y Luo","year":"2012","unstructured":"Luo Y, Teng Z, Wang Q. Development of zein nanoparticles coated with carboxymethyl chitosan for encapsulation and controlled release of vitamin D3. J Agric Food Chem. 2012;60:836\u201343. https:\/\/doi.org\/10.1021\/JF204194Z.","journal-title":"J Agric Food Chem"},{"key":"1367_CR49","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1016\/J.BIOMATERIALS.2003.10.084","volume":"25","author":"J Dong","year":"2004","unstructured":"Dong J, Sun Q, Wang JY. Basic study of corn protein, zein, as a biomaterial in tissue engineering, surface morphology and biocompatibility. Biomaterials. 2004;25:4691\u20137. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2003.10.084.","journal-title":"Biomaterials"},{"key":"1367_CR50","unstructured":"ISO. ISO 10993\u20135:2009 - Biological evaluation of medical devices \u2014 Part 5: Tests for in vitro cytotoxicity. https:\/\/www.iso.org\/standard\/36406.html\/. Accessed 29 Jan 2023."},{"key":"1367_CR51","doi-asserted-by":"publisher","unstructured":"Pereira C, Costa J, Sarmento B, Ara\u00fajo F (2016) Cell-based in vitro models for intestinal permeability studies. Concepts and Models for Drug Permeability Studies: Cell and Tissue based In Vitro Culture Models 57\u201381. https:\/\/doi.org\/10.1016\/B978-0-08-100094-6.00005-5.","DOI":"10.1016\/B978-0-08-100094-6.00005-5"},{"key":"1367_CR52","doi-asserted-by":"publisher","first-page":"9199","DOI":"10.1016\/J.BIOMATERIALS.2014.07.026","volume":"35","author":"F Ara\u00fajo","year":"2014","unstructured":"Ara\u00fajo F, Shrestha N, Shahbazi MA, et al. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials. 2014;35:9199\u2013207. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2014.07.026.","journal-title":"Biomaterials"},{"key":"1367_CR53","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/ANIE.200352540","volume":"43","author":"J Fern\u00e1ndez-Carneado","year":"2004","unstructured":"Fern\u00e1ndez-Carneado J, Kogan MJ, Castel S, Giralt E. Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of gamma-zein. Angew Chem Int Ed Engl. 2004;43:1811\u20134. https:\/\/doi.org\/10.1002\/ANIE.200352540.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1367_CR54","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1039\/C7BM01096F","volume":"6","author":"XJ Du","year":"2018","unstructured":"Du XJ, Wang JL, Iqbal S, et al. The effect of surface charge on oral absorption of polymeric nanoparticles. Biomater Sci. 2018;6:642\u201350. https:\/\/doi.org\/10.1039\/C7BM01096F.","journal-title":"Biomater Sci"},{"key":"1367_CR55","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/J.ADDR.2011.12.009","volume":"64","author":"LM Ensign","year":"2012","unstructured":"Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64:557\u201370. https:\/\/doi.org\/10.1016\/J.ADDR.2011.12.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"1367_CR56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/FCP.12594","volume":"35","author":"J Liu","year":"2021","unstructured":"Liu J, Leng P, Liu Y. Oral drug delivery with nanoparticles into the gastrointestinal mucosa. Fundam Clin Pharmacol. 2021;35:86\u201396. https:\/\/doi.org\/10.1111\/FCP.12594.","journal-title":"Fundam Clin Pharmacol"},{"key":"1367_CR57","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/03639045.2020.1716374","volume":"46","author":"FG Prezotti","year":"2020","unstructured":"Prezotti FG, Boni FI, Ferreira NN, et al. Oral nanoparticles based on gellan gum\/pectin for colon-targeted delivery of resveratrol. Drug Dev Ind Pharm. 2020;46:236\u201345. https:\/\/doi.org\/10.1080\/03639045.2020.1716374.","journal-title":"Drug Dev Ind Pharm"},{"key":"1367_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/J.ADDR.2017.07.019","volume":"124","author":"A Lechanteur","year":"2018","unstructured":"Lechanteur A, das Neves J, Sarmento B,. The role of mucus in cell-based models used to screen mucosal drug delivery. Adv Drug Deliv Rev. 2018;124:50\u201363. https:\/\/doi.org\/10.1016\/J.ADDR.2017.07.019.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01367-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01367-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01367-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:07:50Z","timestamp":1696248470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01367-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1367"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01367-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"13 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the principles of the Declaration of Helsinki. In addition, the commercially available cell lines were only included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declare that they have read the final version of the manuscript and have agreed to its submission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}